Multivalent Vaccines market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Multivalent Vaccines market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Multivalent Vaccines market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Conjugate Vaccines
Inactivated and Subunit Vaccines
Live Attenuated Vaccines
Toxoid Vaccines
Recombinant Vaccines
Segment by Application
Pediatrics
Adults
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
GlaxoSmithKline, plc (U.K.)
Pfizer, Inc (US)
Merck & Co., Inc (US)
Sanofi Pasteur SA (France)
Astellas Pharma Inc. (Japan)
CSL Limited (Australia)
Emergent BioSolutions, Inc (US)
Johnson & Johnson (US)
MedImmune, LLC (US)
Serum Institute of India Pvt. Ltd. (India)
Bavarian Nordic (Denmark)
Mitsubishi Tanabe Pharma Corporation (Japan)
Daiichi Sankyo (Japan)
Protein Sciences Corporation (US)
Panacea Biotec (India)
